Silence Therapeutics
Yahoo Finance • yesterday
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
European equities traded in the US as American depositary receipts began the week little changed lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 19 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were lower late Thursday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 22 days ago
European Equities Traded in the US as American Depositary Receipts Climb in Monday Trading
European equities traded in the US as American depositary receipts were tracking sharply higher late PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks
As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth pot... Full story
Yahoo Finance • 2 years ago
Silence Therapeutics plc's (NASDAQ:SLN) 65% Price Boost Is Out Of Tune With Revenues
Silence Therapeutics plc (NASDAQ:SLN) shares have had a really impressive month, gaining 65% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still d... Full story
Yahoo Finance • 2 years ago
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint LONDON, November 01, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq:... Full story
Yahoo Finance • 3 years ago
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
LONDON, April 25, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precisi... Full story
Yahoo Finance • 3 years ago
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
LONDON, January 12, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through preci... Full story
